University of Toledo Validates University Health Network In-Vitro Data

Toronto, Ontario – December 9, 2014 Theralase Technologies Inc. (“Theralase”) (TSXV: TLT) (TLTFF: OTC Pink®) announced today that the University of Toledo has conducted in-vitro Photo Dynamic Compound (“PDC”) experimentation that replicates preclinical results obtained earlier by Princess Margaret Cancer Centre, University Health Network (“UHN”), thus validating the Theralase PDC technology at two world renowned institutions.

Theralase strategically partnered with the University of Toledo to confirm its in-vitro preclinical PDC results because of the expertise resident in the urology department led by Steve Selman, MD, FACS, Chair and Professor of Urology and Director of Urological Research, University of Toledo, Toledo, Ohio.

Screen Shot 2014-12-10 at 10.17.59 AM

Dr. Selman stated that, “I am pleased that we have been given the opportunity to work with Theralase and UHN on the preclinical validation of the Theralase PDC technology. The preclinical results we have obtained mirror the results obtained by UHN and thus provide Theralase the comfort that their PDC technology has been independently validated by two highly regarded teaching hospitals. I look forward to reporting out on our preclinical in-vivo orthotopic animal results later this month.”

Lothar Lilge PhD, Senior Scientist, Princess Margaret Cancer Centre, University Health Network stated that, “I have had a long scientific working relationship with the University of Toledo, Dr. Selman and his staff and appreciate the opportunity to collaborate together in the preclinical validation of the Theralase PDC technology. We are now in the position to complete our preclinical orthotopic rat model experimentation in conjunction with the University of Toledo and report out to all interested parties, the results of this fascinating research by the end of this year.”

Roger Dumoulin-White, President and CEO of Theralase stated that, “Theralase greatly appreciates the opportunity to work with such world renowned institutions as the University of Toledo and UHN in the validation of our PDC technology. It is through the experience and knowledge of strong partners that greatness is achieved and our PDC technology has the opportunity to be commercialized in the not too distant future.”


About Theralase Technologies Inc.

Founded in 1994, Theralase Technologies Inc. (“Theralase®”) (TSXV: TLT) (TLTFF: OTC Pink®) designs, manufactures and markets patented super-pulsed laser technology used for the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing. Theralase has sold over 1,200 systems to licensed healthcare practitioners, including: medical doctors, chiropractors, physical therapists and athletic therapists. Theralase has been very successful in healing nerve, muscle and joint conditions in clinical practice and now Theralase’s scientists and clinicians are investigating the application of its lasers in the destruction of cancer using specially designed molecules called Photo Dynamic Compounds (“PDCs”), which localize to the DNA of cancer cells and when light activated, destroy the cancer cells.

Additional information is available at and .

This press release contains forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information:

Roger Dumoulin-White

President & CEO, Theralase Technologies Inc.

1.866.THE.LASE (843-5273) ext. 225

416.699.LASE (5273) ext. 225